Analysis of choline alfoscerate effectiveness in chronic ocular ischemic syndrome

Abstract

Development and application of an adequate combination therapy for patients with ocular ischemic syndrome has yielded an increase in visual acuity, visual fields, and the mean light sensitivity of the retina as well as an improvement of ocular hemodynamics.

Role of Choline in Ocular Diseases

“…Ocular ischemic syndrome is a rare severe ocular disease caused by ocular hypoperfusion due to stenosis or occlusion of the common or internal carotid artery [ 105 ]. In patients with ocular ischemic syndrome, a more rapid and stable improvement in visual acuity was observed in the choline alfoscerate group [ 106 ].…”

A comparative evaluation of the efficacy of dimethylaminoethanol derivative 7–16, C7070 and picamilon in correction of experimental hypertensive neuroretinopathy

“…Derivatives of DMAE, the precursors of ACh, are referred to nootropic agents: deanol aceglumate and meclofenoxate. The literature data show the widespread use of nootropic drugs in ophthalmic practice: clinical and functional studies showed faster and more stable improvement in visual acuity in the group of patients with chronic ocular ischemic syndrome by using choline alfoscerate (Kamilov et al 2016); the use of citicoline showed a beneficial effect in the treatment of amblyopia and improved the retinal function (Matteucci et al 2014, Roberti et al 2015; vinpocetine modulated metabolic activity and retinal function during retinal ischemia (Nivison-Smith et al 2015), etc. Substance C7070, 3-(1H-benzimidazol-2-il)-1,2,2-trimethylcyclopentancarbonic acid, is a non-selective agonist of imidazoline receptors type I, II.…”